230 related articles for article (PubMed ID: 24978678)
21. Microbe-Dependent Exacerbated Alveolar Bone Destruction in Heterozygous Cherubism Mice.
Kittaka M; Yoshimoto T; Schlosser C; Kajiya M; Kurihara H; Reichenberger EJ; Ueki Y
JBMR Plus; 2020 Jun; 4(6):e10352. PubMed ID: 32537546
[TBL] [Abstract][Full Text] [Related]
22. Rescue of a cherubism bone marrow stromal culture phenotype by reducing TGFβ signaling.
Liu Y; Sharma T; Chen IP; Reichenberger E; Ueki Y; Arif Y; Parisi D; Maye P
Bone; 2018 Jun; 111():28-35. PubMed ID: 29530719
[TBL] [Abstract][Full Text] [Related]
23. Novel treatment of a rare genetic bone disease.
McMahon MS
Orthopedics; 2007 Feb; 30(2):91. PubMed ID: 17323628
[No Abstract] [Full Text] [Related]
24. Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-alpha genetic deletion.
Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Centorrino T; Siriwardena AK; Cuzzocrea S
Shock; 2007 May; 27(5):542-51. PubMed ID: 17438460
[TBL] [Abstract][Full Text] [Related]
25. Tlr2/4-Mediated Hyperinflammation Promotes Cherubism-Like Jawbone Expansion in Sh3bp2 (P416R) Knockin Mice.
Fujii Y; Monteiro N; Sah SK; Javaheri H; Ueki Y; Fan Z; Reichenberger EJ; Chen IP
JBMR Plus; 2022 Jan; 6(1):e10562. PubMed ID: 35079675
[TBL] [Abstract][Full Text] [Related]
26. Loss-of-function
Kittaka M; Mizuno N; Morino H; Yoshimoto T; Zhu T; Liu S; Wang Z; Mayahara K; Iio K; Kondo K; Kondo T; Hayashi T; Coghlan S; Teno Y; Doan AAP; Levitan M; Choi RB; Matsuda S; Ouhara K; Wan J; Cassidy AM; Pelletier S; Nampoothiri S; Urtizberea AJ; Robling AG; Ono M; Kawakami H; Reichenberger EJ; Ueki Y
JBMR Plus; 2024 Jun; 8(6):ziae050. PubMed ID: 38699440
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complications.
Chastre A; Bélanger M; Beauchesne E; Nguyen BN; Desjardins P; Butterworth RF
PLoS One; 2012; 7(11):e49670. PubMed ID: 23166746
[TBL] [Abstract][Full Text] [Related]
28. Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus.
Venegas-Pont M; Manigrasso MB; Grifoni SC; LaMarca BB; Maric C; Racusen LC; Glover PH; Jones AV; Drummond HA; Ryan MJ
Hypertension; 2010 Oct; 56(4):643-9. PubMed ID: 20696988
[TBL] [Abstract][Full Text] [Related]
29. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation.
Lietman SA; Kalinchinko N; Deng X; Kohanski R; Levine MA
Hum Mutat; 2006 Jul; 27(7):717-8. PubMed ID: 16786512
[TBL] [Abstract][Full Text] [Related]
30. Molecular and cellular characterizations of human cherubism: disease aggressiveness depends on osteoclast differentiation.
Kadlub N; Sessiecq Q; Mandavit M; L'Hermine AC; Badoual C; Galmiche L; Berdal A; Descroix V; Picard A; Coudert AE
Orphanet J Rare Dis; 2018 Sep; 13(1):166. PubMed ID: 30236129
[TBL] [Abstract][Full Text] [Related]
31. Etanercept prevents decrease of cochlear blood flow dose-dependently caused by tumor necrosis factor alpha.
Ihler F; Sharaf K; Bertlich M; Strieth S; Reichel CA; Berghaus A; Canis M
Ann Otol Rhinol Laryngol; 2013 Jul; 122(7):468-73. PubMed ID: 23951701
[TBL] [Abstract][Full Text] [Related]
32. Etanercept prevents TNF-α mediated mandibular bone loss in FcγRIIb-/- lupus model.
Sakunrangsit N; Metheepakornchai P; Kumpunya S; Greenblatt MB; Leelahavanichkul A; Pisitkun P; Lotinun S
PLoS One; 2021; 16(4):e0250215. PubMed ID: 33861790
[TBL] [Abstract][Full Text] [Related]
33. Cherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages.
Prod'Homme V; Boyer L; Dubois N; Mallavialle A; Munro P; Mouska X; Coste I; Rottapel R; Tartare-Deckert S; Deckert M
J Clin Invest; 2015 Apr; 125(4):1396-400. PubMed ID: 25705883
[TBL] [Abstract][Full Text] [Related]
34. Role of TNF-alpha in lung tight junction alteration in mouse model of acute lung inflammation.
Mazzon E; Cuzzocrea S
Respir Res; 2007 Oct; 8(1):75. PubMed ID: 17971210
[TBL] [Abstract][Full Text] [Related]
35. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis.
Lories RJ; Derese I; de Bari C; Luyten FP
Arthritis Rheum; 2007 Feb; 56(2):489-97. PubMed ID: 17265484
[TBL] [Abstract][Full Text] [Related]
36. Loss of SH3 domain-binding protein 2 function suppresses bone destruction in tumor necrosis factor-driven and collagen-induced arthritis in mice.
Mukai T; Gallant R; Ishida S; Kittaka M; Yoshitaka T; Fox DA; Morita Y; Nishida K; Rottapel R; Ueki Y
Arthritis Rheumatol; 2015 Mar; 67(3):656-67. PubMed ID: 25470448
[TBL] [Abstract][Full Text] [Related]
37. Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Caminiti R; Esposito E; Di Bella P; Cuzzocrea S
Shock; 2008 May; 29(5):560-71. PubMed ID: 17724436
[TBL] [Abstract][Full Text] [Related]
38. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism.
Ueki Y; Tiziani V; Santanna C; Fukai N; Maulik C; Garfinkle J; Ninomiya C; doAmaral C; Peters H; Habal M; Rhee-Morris L; Doss JB; Kreiborg S; Olsen BR; Reichenberger E
Nat Genet; 2001 Jun; 28(2):125-6. PubMed ID: 11381256
[TBL] [Abstract][Full Text] [Related]
39. Novel nucleotide mutation leading to a recurrent amino acid alteration in SH3BP2 in a patient with cherubism.
Sangu N; Shimosato T; Inoda H; Shimada S; Shimojima K; Ando T; Yamamoto T
Congenit Anom (Kyoto); 2013 Dec; 53(4):166-9. PubMed ID: 24712477
[TBL] [Abstract][Full Text] [Related]
40. [SH3BP2 heterozygous mutation amplifies macrophage inflammatory responses to infection in a mouse model of cherubism].
Deckert M; Prod'Homme V
Med Sci (Paris); 2015; 31(6-7):589-91. PubMed ID: 26152156
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
